ReferenceRRK4633

Sequencing Based Analysis of SLE

Sequencing Based Genetic Analysis of Systemic Lupus Erythematosus (SLE)

Research Summary

The aim of our research is to discover the genetic factors that increase the risk of developing SLE using high-throughput genome sequencing technologies. This type of sequencing allows more variants to be sequenced with greater accuracy.Using DNA together with clinical information we can look for differences between people with SLE and those unaffected by the disease. We can use this to identify genetic differences that are more prevalent in SLE patients and then ask how these factors affect the immune system and how they influence the nature and severity of the disease.We will collect blood from patients with SLE who satisfy the specific criteria for disease classification as well as healthy controls. The study will be explained to the potential participants and informed written consent for study participation and peripheral venepuncture will be obtained.Patients are asked to complete a short questionnaire about how they have been affected by SLE and to give a blood sample (40ml or 8 tsp). To do this they either visit our department at Guy’s or St Thomas’ Hospital or we can send a blood collection pack that the patient can take to their GP or local hospital for sample collection which will then be sent back to us.We will use current technologies to detect genetic differences in participants’ DNA. Some of the differences will be unique to the individual. Such unique genetic differences may provide valuable insight into how the disease develops. Some patients may be contacted regarding other studies that we run. Participation in these studies is completely voluntary. Though the study will represent no direct benefit to participants we hope this research will lead to increased future understanding of disease mechanism.Funding has been provided by the Wellcome Trust ARUK and an ESG1 (Fp7) programme grant.

Research Overview
Sponsor King's College London
Project Status Open
Proposed End Date 01/10/2022
Study Run through CRF? Yes
Target number of patients agreed to recruit 75
Recruitment so far 73